“These results are really exciting. This could be a new front in the fight against MS.”
Researchers at Oregon Health & Science University have discovered that an antioxidant designed by scientists more than a dozen years ago to fight damage within human cells significantly helps symptoms in mice that have a multiple sclerosis-like disease.
The antioxidant — called MitoQ — has shown some promise in fighting neurodegenerative diseases. But this is the first time it has been shown to significantly reverse an MS-like disease in an animal.
The discovery could lead to an entirely new way to treat multiple sclerosis, which affects more than 2.3 million people worldwide.
Multiple sclerosis occurs when the body’s immune system attacks the myelin, or the protective sheath, surrounding nerve fibers of the central nervous system. Some underlying nerve fibers are destroyed. Resulting symptoms can include blurred vision and blindness, loss of balance, slurred speech, tremors, numbness and problems with memory and concentration.
The antioxidant research was published in the December edition of Biochimica et Biophysica Acta Molecular Basis of Disease. The research team was led by P. Hemachandra Reddy, Ph.D., an associate scientist in the Division of Neuroscience at OHSU’s Oregon National Primate Research Center.
To conduct their study, the researchers induced mice to contract a disease called experimental autoimmune encephalomyelitis, or EAE, which is very similar to MS in humans. They separated mice into four groups: a group with EAE only; a group that was given the EAE, then treated with the MitoQ; a third group that was given the MitoQ first, then given the EAE; and a fourth “control” group of mice without EAE and without any other treatment.
After 14 days, the EAE mice that had been treated with the MitoQ exhibited reduced inflammatory markers and increased neuronal activity in the spinal cord — an affected brain region in MS — that showed their EAE symptoms were being improved by the treatment. The mice also showed reduced loss of axons, or nerve fibers and reduced neurological disabilities associated with the EAE. The mice that had been pre-treated with the MitoQ showed the least problems. The mice that had been treated with MitoQ after EAE also showed many fewer problems than mice who were just induced to get the EAE and then given no treatment.
“The MitoQ also significantly reduced inflammation of the neurons and reduced demyelination,” Reddy said. “These results are really exciting. This could be a new front in the fight against MS.”
Even if the treatment continues to show promise, testing in humans would be years away. The next steps for Reddy’s team will be to understand the mechanisms of MitoQ neuroprotection in different regions of the brain, and how MitoQ protects mitochondria within the brain cells of the EAE mice. Mitochondria, components within all human cells, convert energy into forms that are usable by the cell.
There is a built-in advantage with MitoQ. Unlike many new drugs, MitoQ has been tested for safety in numerous clinical trails with humans. Since its development in the late 1990s, researchers have tested MitoQ’s ability to decrease oxidative damage in mitochondria.
The Latest on: Multiple sclerosis
via Google News
The Latest on: Multiple sclerosis
- Multiple Sclerosis Market: Global Product Intelligence, Analysis, Opportunities and Forecast to 2025on December 2, 2019 at 9:17 am
Pune, India -- (SBWIRE) -- 12/02/2019 -- Infinium Global Research has recently published a report on "Multiple Sclerosis Market(Treatment Modality - injectable Agents, and Oral Agents; Application - ...
- First-in-kind Human 3-dimensional Models of Parkinson’s Disease and Progressive Multiple Sclerosis Launching to the International Space Stationon December 2, 2019 at 7:54 am
The NSCF-funded collaboration between researchers at the NYSCF Research Institute and Aspen Neuroscience will perform the first study of long-term cell cultures of patient-derived induced pluripotent ...
- Treating multiple sclerosis with the help of the gut microbiomeon December 2, 2019 at 5:21 am
A team at Brigham and Women's Hospital has a unique approach to studying the microbiome and its relation to multiple sclerosis (MS)—one that could provide a completely new way to treat the ...
- Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosison December 2, 2019 at 2:23 am
Differently from the adult multiple sclerosis (MS) population, the predictive value of cognitive impairment in early-onset MS is still unknown. We aim to evaluate whether cognitive performances at ...
- Year in Review: Multiple Sclerosison December 1, 2019 at 9:24 am
Multiple sclerosis (MS) news in 2019 focused largely on drugs -- new drugs, old drugs, drug costs, and treatment strategies -- but new vaccination guidelines and biomarker research also earned ...
- Biogen will offer discounts to a health plan if patients say its multiple sclerosis drugs don’t workon November 27, 2019 at 9:06 am
In a twist on value-based contracting, a drug maker has agreed to offer a larger discount that a commercial health plan will receive for medicines – but only based on outcomes that patients report. In ...
- Investigators narrow in on a microRNA for treating multiple sclerosison November 26, 2019 at 8:03 am
It turns out the gut is full of surprises. And one of those surprises may have offered up a key for unlocking a new way of treating multiple sclerosis (MS). Investigators from Brigham and Women's ...
- New method to separate two variants of common herpes virus linked to multiple sclerosison November 26, 2019 at 7:40 am
Researchers at Karolinska Institutet have developed a new method to separate between two different types of a common herpes virus (HHV-6) that has been linked to multiple sclerosis. By analyzing ...
- Multiple sclerosis linked to variant of common herpes virus through new methodon November 26, 2019 at 3:57 am
Researchers at Karolinska Institutet have developed a new method to separate between two types of a common herpes virus (HHV-6) that has been linked to multiple sclerosis (MS). By analyzing antibodies ...
- Study shows the progression of multiple sclerosis can be slowedon November 25, 2019 at 12:07 am
Multiple sclerosis (MS) is difficult to diagnose, and, as yet, it has no cure. However, according to new research, it may be possible to slow its progression without some of the health risks ...
via Bing News